Tilray Brands’ Aphria RX GmbH Receives License Under Germany’s New Cannabis Law

LOS ANGELES- Tilray Brands, Inc. announced that its German subsidiary, Aphria RX GmbH, has received a cultivation license under Germany’s newly enacted adult-use cannabis legalization law. The facility, previously licensed in 2019 for Germany’s medical cannabis program, can now cultivate a broader range of cannabis products, expanding from three strains to 31 under the new Cannabis Act.

The new license allows Aphria RX to further develop its cannabis cultivation and manufacturing capabilities. Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International, expressed enthusiasm for the expanded access to high-quality medical cannabis and the enhanced treatment options for patients.

Germany’s legalization law, effective April 1, permits adults aged 18 and older to possess and consume cannabis, though the market is not fully regulated for commercial sales. Currently, cannabis access is largely limited to homegrown sources and newly established cannabis clubs.

Additionally, Tilray Brands recently received approval for a new medical cannabis product, Tilray Solucao Oral THC10, in Portugal, marking the company’s continued international expansion in medical cannabis. This product is the third medical cannabis offering approved by Tilray in Portugal this year, following previous approvals for other cannabis-based treatments.